| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;92:114-119.)
© 1995 American Heart Association, Inc.
Articles |
Role of Endothelin-1 in Beagles With Dehydromonocrotaline-Induced Pulmonary Hypertension
From the Department of Surgery, Division II, Kobe University School of Medicine, Kobe, Japan.
Correspondence to Morihito Okada, MD, Department of Surgery, Division II, Kobe University School of Medicine, Kusunoki-cho 7-5-2, Chuo-ku, 650 Kobe City, Japan.
Background Although plasma levels of endothelin-1 (ET-1) increase in patients with pulmonary hypertension (PH), its role in PH is unknown. We investigated the contribution of endogenous ET-1 to cardiopulmonary changes in beagles with dehydromonocrotaline (DMCT)-induced PH.
Methods and Results Eight 3-month-old beagles were given a single injection of 3 mg/kg DMCT via the right atrium. During the 8 weeks after injection, the mean pulmonary arterial pressure (PAP) and plasma ET-1 level increased significantly from 11.6±2.3 to 35.9±7.1 mm Hg and from 1.24±0.25 to 3.25±0.94 pg/mL, respectively. In controls, ET-1 infusion elevated the systemic arterial pressure (SAP) but did not alter PAP. In PH beagles, ET-1 infusion increased SAP, which was attenuated by FR139317 (an endothelin type [ET] A receptor antagonist), and produced a dose-dependent decrease in PAP, which was attenuated by RES-701-1 (an ETB receptor antagonist). In PH beagles, FR139317 infusion decreased PAP, and RES-701-1 infusion increased PAP. Sarafotoxin S6c (an ETB agonist) infusion decreased PAP in PH beagles.
Conclusions These results suggest that endogenous ET-1 is elevated in PH disease and may mitigate PH by acting on ETB receptors.
Key Words: pulmonary heart disease • endothelin
This article has been cited by other articles:
 |
|
 |
|
  K. Kimura, M. Ieda, H. Kanazawa, T. Yagi, M. Tsunoda, S.-i. Ninomiya, H. Kurosawa, K. Yoshimi, H. Mochizuki, K. Yamazaki, et al. Cardiac Sympathetic Rejuvenation: A Link Between Nerve Function and Cardiac Hypertrophy Circ. Res., June 22, 2007; 100(12): 1755 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rondelet, R. Van Beneden, F. Kerbaul, S. Motte, P. Fesler, K. McEntee, S. Brimioulle, J-M. Ketelslegers, and R. Naeije Expression of the serotonin 1b receptor in experimental pulmonary hypertension Eur. Respir. J., September 1, 2003; 22(3): 408 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Jasmin, M. Lucas, P. Cernacek, and J. Dupuis Effectiveness of a Nonselective ETA/B and a Selective ETA Antagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension Circulation, January 16, 2001; 103(2): 314 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A Markewitz, I. S Farrukh, Y. Chen, Y. Li, and J. R Michael Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells: effects of transforming growth factor-{beta} and hypoxia Cardiovasc Res, January 1, 2001; 49(1): 200 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupuis and S. Prie The ETA-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(1): 33 - 39. [Abstract] [PDF]
|
|
|
|
|
|
J. Dupuis, J.-L. Rouleau, and P. Cernacek Reduced Pulmonary Clearance of Endothelin-1 Contributes to the Increase of Circulating Levels in Heart Failure Secondary to Myocardial Infarction Circulation, October 20, 1998; 98(16): 1684 - 1687. [Abstract] [Full Text] [PDF]
|
|